Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tissue Sodium in Pre-hypertensive Patients
NCT02236520Phase 2Completed
- Sponsor
- Vanderbilt University
- Start
- Sep 2014
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of spironolactone in hypertension (HTN) (4 arms), sponsored by Vanderbilt University. Primary endpoint: Change in Tissue Sodium Concentration Measured Using Sodium Magnetic Resonance Imaging (NaMRI) at 8 weeks. Started Sep 2014; status: completed.
02
Drugs
spironolactone
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02236520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02236520.